Cancer Vaccine Could Go 'Above and Beyond Standard of Care'

Moderna and Merck have initiated V940-001, a phase 3 study evaluating vaccine mRNA-4157 and anti-PD-1 therapy Keytruda as postsurgical treatment for stage 2B to 4 melanoma.

Related Keywords

Jeffreys Weber , Kyle Holen Moderna , Drug Administration , Grossman School Of Medicine , Langone Perlmutter Cancer Center , Merck Research Laboratories , Perlmutter Cancer Center , Isaac Perlmutter Professor , Marjorie Green , Breakthrough Therapy Designation , News , Melanoma , Cancer Vaccine , Keytruda ,